Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

EUROHEADPAIN · Mechanisms and Treatment of Migraine and its Chronification

FP7Status: CLOSED1 February 201431 January 2017EU funding €5,996,726

Migraine is a common brain disorder, typically characterised by recurring, incapacitating attacks of 1-3 days of severe headache, autonomic dysfunction, and sometimes aura symptoms. The disease affects 15% of all European citizens including children, ranks among the WHO top 12 of most disabling and undertreated disorders, and is responsible for the highest socio-economic burden of any brain ailment in Europe.Migraine attacks typically strike bi-monthly, and in 25% of patients once a week or more. Many patients may progress to “chronic migraine” with near-daily headaches and high disability (chronification). There is desperate need of effective prophylactic treatments to prevent attacks and chronification. Current medications are only moderately effective and often poorly tolerated, mainly due to lack of understanding of how attacks are triggered and why their frequency may increase so dramatically. Overuse of painkillers and triptans, are recognised risk factors for chronification, as are comorbid depression, stress, and obesity. Central sensitisation of pain signalling pathways appears to be pivotal to the chronification proces.EUROHEADPAIN will use established and evolving human and translational animal models to: (a) identify pathways and biomarkers for the triggering and chronification of migraine attacks; (b) decipher the modulatory effects of (hypothalamic) brain circuitries on trigeminal processing, sensitisation, and chronification; (c) assess the effects and mode of action of migraine-provoking molecules; and (d) evaluate the efficacy and mode of action of neuromodulation (in collaboration with an SME) and second messenger-blocking drugs in the treatment of chronic migraine. We expect important spin-offs to the understanding of other chronic pain disorders. The pharmaceutical industry will be engaged once treatable targets have been identified to develop novel treatments to reduce the disability and socio-economic burden due to migraine.

Consortium · 14 organisations

coordinator

ACADEMISCH ZIEKENHUIS LEIDEN

NL · €1,511,738

participant

REGION HOVEDSTADEN

DK · €711,320

participant

UNIVERSITE DE LIEGE

BE · €592,544

participant

QUEENSLAND UNIVERSITY OF TECHNOLOGY - QLD QUT

AU

participant

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG

DE · €552,680

participant

HELSINGIN YLIOPISTO

FI · €1,039,364

participant

GENOME RESEARCH LIMITED

UK

participant

SCUOLA INTERNAZIONALE SUPERIORE DI STUDI AVANZATI DI TRIESTE

IT · €333,680

participant

QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

AU

participant

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

DE · €468,440

participant

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

US

participant

SZEGEDI TUDOMANYEGYETEM

HU · €170,960

participant

CEFALY TECHNOLOGY

BE · €121,640

participant

KING'S COLLEGE LONDON

UK · €494,360

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.